Skip to content
Search

Latest Stories

Trump urged to prioritise removal of trade barriers with India

Top US lawmakers have urged president Donald Trump to prioritise the elimination of trade and investment "barriers" by India during his upcoming meeting with India prime minister Narendra Modi, saying they "significantly harm" American businesses and workers.

The four lawmakers also claimed that India has imposed several new significant barriers that have harmed US producers across all sectors of the American economy, including services, manufacturing, and agriculture.


"We write to you ahead of the upcoming visit by prime minister Narendra Modi to urge you to prioritise the elimination of Indian trade and investment barriers that significantly harm American businesses and workers," the lawmakers said.

The four lawmakers are - Senator Orrin Hatch, Chairman of the Senate Committee on Finance and Senator Ron Wyden, Ranking Member of the Senate Finance Committee, Congressman Kevin Brady, Chairman of the House Committee on Ways and Means and Congressman Richard Neal, Ranking Member of the House Committee on Ways and Means.

"While Indian businesses continue to benefit from open US markets, India has failed to eliminate, or even address concretely, multiple trade and investment barriers that have been the focus of recent bilateral and multilateral fora," the letter said.

"At the same time, India has imposed several new significant barriers that have harmed US producers across all sectors of our economy, including services, manufacturing, and agriculture. prime minister Modi's visit provides an opportunity once again to press India for results," the lawmakers said in the letter dated June 23.

The lawmakers said that in recent years the US and India have sought to strengthen economic engagement through the bilateral Strategic and Commercial Dialogue and the Trade Policy Forum (TPF).

"Yet these high-level discussions have not resulted in the elimination of major trade and investment barriers or even deterred India from imposing new barriers. Many sectors of the Indian economy remain highly and unjustifiably protected, and India continues to be a difficult place for American companies to do business," they wrote.

This reality is buttressed by the results of the 2017 edition of the World Bank's Doing Business report, which ranks India 130 out of 190 countries, the lowest ranking for any G- 20 country -for ease of doing business, they noted.

Noting that India remains an important bilateral trade and investment partner for the US, the lawmakers said the two countries are now have the largest bilateral trade and investment flows ever recorded in their relationship.

"Nevertheless, as a result of India's persistent failure to enact market-based reforms and resolve significant and discriminatory impediments to trade and investment, the US- India economic relationship severely underperforms. Bilateral trade and investment is small considering the size of the countries' economies and the scale of the potential relationship -India accounts for less than two per cent of total US exports of goods and services and less than one percent of the stock of US overseas investment," they said.

The letter says that the US International Trade Commission determined in a 2014 report that "(i) tariff and investment restrictions were fully eliminated [by India] and standards of IP protection were made comparable to US and Western European levels, US exports to India would rise by two-thirds, and US investment in India would roughly double".

Consumers, businesses, and workers in both the US and India could gain enormously from enhanced bilateral trade and investment.

But achieving the full potential of this relationship requires the actual removal of India's economic barriers, they said.

"These barriers are prevalent in multiple sectors and include high tariffs, inadequate protection of intellectual property rights (IPR), inconsistent and nontransparent licensing and regulatory practices, and various other restrictions," the lawmakers said.

Regarding IPR protection, the four Congressmen said they continue to have concerns about India's system for providing protection for patents, trademarks, and copyrights.

"India's weak standards and insufficient enforcement remain an area of concern for US right holders, including with respect to pharmaceutical patents and in the area of copyright protection, where we understand that India has not enacted meaningful laws to prevent cam cording in cinemas, which has led to rampant infringement," they wrote.

With regard to India's licensing and regulatory practices, discriminatory determinations and inconsistent and nontransparent approval processes have hampered US trade and investment, they alleged.

For example, India maintains a variety of forced localisation measures on solar and information technology products and enforces duplicative in-country security testing requirements for telecommunications equipment, the letter noted.

Other regulatory barriers include unnecessarily slow and opaque approval processes for biotechnology products; sanitary and phytosanitary standards that appear to be non-science based; burdensome import and customs procedures; significant limitations on foreign participation in professional services; and restrictive foreign equity caps for financial, retail, and other major services sectors.

In a statement, Patrick Kilbride, Vice President of International Intellectual Property, Global Intellectual Property Center said from the halls of the Congress to the Trump administration, US leaders have placed an emphasis on ensuring American innovation is respected abroad.

"In India, that includes strengthening IP standards to address issues with patentability, computer-related inventions, and copyright infringement. Prime Minister Modi's visit presents an opportunity to revisit these issues and renew India s commitment to policies that will benefit both American and Indian innovators," Kilbride said.

More For You

modi-trump-getty
Trump shakes hands with Modi during a joint press conference at Hyderabad House in New Delhi on February 25, 2020. (Photo: Getty Images)

Key issues in India, US trade talks

TRADE talks between India and the US have hit a roadblock over disagreements on duties for auto components, steel and farm goods, Indian government sources said to Reuters, dashing hopes of reaching an interim deal ahead of president Donald Trump's July 9 deadline to impose reciprocal tariffs.

Here are the key issues at play:

Keep ReadingShow less
Anil Agarwal

Vedanta Resources, which is based in the UK and owned by Indian billionaire Anil Agarwal, has been working on reducing its debt. (Photo credit: Getty Images)

Getty Images

Anil Agarwal’s Vedanta Resources signs £438 million refinancing deal

VEDANTA LTD said on Thursday that its parent company, Vedanta Resources, has signed a loan facility agreement worth up to £438 million with international banks to refinance existing debt.

The refinancing move, where old loans are replaced by new ones, often at better terms like lower interest rates, has led ratings agencies such as S&P Global Ratings and Moody's to upgrade their outlook on the company this year.

Keep ReadingShow less
Trump-Getty

Trump said that while deals are being made with some countries, others may face tariffs.

Getty Images

Trump says major trade deal with India may be finalised soon

US PRESIDENT Donald Trump on Friday said a "very big" trade deal could be finalised with India, suggesting significant movement in the ongoing negotiations between the two countries.

“We are having some great deals. We have one coming up, maybe with India. Very big one. Where we're going to open up India," Trump said at the “Big Beautiful Bill” event at the White House.

Keep ReadingShow less
Asda suffers nearly £600m loss as debt and IT costs surge

Asda co-ownerMohsin Issa. (Photo: Asda)

Asda suffers nearly £600m loss as debt and IT costs surge

ASDA, one of Britain’s largest supermarkets, has reported a pre-tax loss of £599 million for 2024, swinging sharply from a £180 million profit the previous year.

The loss comes despite total sales rising by over £1 billion to £26.8bn, as the retailer faces mounting debt costs, falling sales, and spiralling spending on a major IT overhaul, the Telegraph reported.

Keep ReadingShow less
Mounjaro

Mounjaro, or tirzepatide, is part of a new class of weight-loss medications, with trials showing patients losing an average of 20 per cent of their body weight after 72 weeks.

Reuters

Lilly to sell Mounjaro pens in India as Wegovy enters market

ELI LILLY said on Thursday that it has received approval from India's drug regulator to launch pre-filled injector pens of its weight-loss drug, Mounjaro.

The move gives the company more options to compete with Novo Nordisk, which recently launched its weight-loss drug Wegovy in the country.

Keep ReadingShow less